2396-61-4

Usage

Uses

Used in Pharmaceutical Synthesis:
3,3'-Oxydipropanol is used as an intermediate in the synthesis of 3,3''-[Oxybis(3,1-propanediyloxy)]bis[1-propanol] (O870290) for its ability to form essential linkages in the synthesis process.
Used in Antidysuria Drug Synthesis:
3,3'-Oxydipropanol is used as a reagent in the synthesis of Silodosin (S465000), an antidysuria drug, for its role in creating the necessary chemical structure of the drug.
Used in Antiviral Drug Synthesis:
3,3'-Oxydipropanol is also used as a reagent in the preparation of aryloxyalkyl derivatives of adenine, which possess antiviral activity, due to its ability to form the required chemical bonds in the synthesis of these compounds.

Upstream product

• 504-63-2 trimethyleneglycol 
• 7647-01-0 hydrogenchloride 
• 5465-07-6 β-hydroxyethyl-2 dioxanne-1,3 
• 17615-28-0 di-n-propyl 4-oxa-1,7-heptanedioate 
• 57-55-6 propylene glycol 
• 75-56-9 methyloxirane 
• 102275-51-4 2-<2-(2-hydroxyethoxy)ethyl>-1,3-dioxane 
• 5961-83-1 3-(2-carboxyethoxy)propionic acid 
• 1656-48-0 2-cyanoethyl ether 
• 635677-60-0 1-benzyloxy-3-(3-benzyloxy-propoxy)propane 
• 7783-06-4 hydrogen sulfide 
• 34399-67-2 1-bromo-3-(1-ethoxyethoxy)propane 
• 627-30-5 1-chloro-3-hydroxypropane 
• 17615-27-9 diethyl-4-oxa-heptanedioate 

Downstream Products

• 504-63-2 trimethyleneglycol 
• 55333-98-7 hexapropyleneglycol 
• 55005-96-4 oxybis(propane-3,1-diyl) bis(4-methylbenzenesulfonate) 
• 99616-80-5 3-oxaheptanediol monotoluene-p-sulphonate 
• 1549672-94-7 C₁₃H₁₉NO 
• 110-91-8 morpholine 
• 1417792-20-1 C₃₃H₃₁ClFN₃O₉S 
• 1417792-37-0 C₃₅H₃₅ClFN₃O₉S 
• 1417792-36-9 C₂₆H₂₈ClFN₂O₆ 
• 1417792-35-8 C₂₆H₂₆ClFN₂O₈ 
• 1417792-33-6 C₁₃H₁₈ClNO₆ 
• 55333-89-6 5,9,13,17,21-Pentaoxapentacosandinitril 
• 58929-41-2 [3-(4-Chloro-phenoxy)-propyl]-(3-{3-[[3-(4-chloro-phenoxy)-propyl]-(2-methoxy-ethyl)-amino]-propoxy}-propyl)-(2-methoxy-ethyl)-amine 
• 58929-37-6 [2-(2-Chloro-phenoxy)-ethyl]-(3-{3-[[2-(2-chloro-phenoxy)-ethyl]-(2-methoxy-ethyl)-amino]-propoxy}-propyl)-(2-methoxy-ethyl)-amine 

Relevant academic research and scientific papers

3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF

The present disclosure provides a compound of Formula (I′): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein Rx, X1, X2, and R1 are as defined herein, and methods of making and using same.

METHOD FOR PRODUCING GLYCOL FROM OXIRANE COMPOUND

The objective of the present invention is to provide a method for the highly selective production of dipropylene glycol containing 1,1'-oxybis-2-propanol in a proportion of 0.10 to 0.70 and/or tripropylene glycol containing 1,1'-[(1-methyl-1,2-ethanediyl)bis(oxy)]bis-2-propanol in a proportion of 0.10 to 0.70. The present invention is a method for producing dipropylene glycol containing 1,1'-oxybis-2-propanol in a proportion of 0.10 to 0.70 and/or tripropylene glycol containing 1,1'-[(1-methyl-1,2-ethanediyl)bis(oxy)]bis-2-propanol in a proportion of 0.10 to 0.70, the method comprising a reaction step of making a reactant comprising propylene oxide and water react in the presence of a catalyst, wherein the catalyst comprises at least one element selected from the group consisting of vanadium, niobium, and tantalum, and the Hammett acidity function (H) of the catalyst satisfies H ≤ 9.3.

AQUEOUS PIGMENT DISPERSION CONTAINING LOW MOLECULAR WEIGHT POLYTRIMETHYLENE ETHER GLYCOL

The present disclosure is directed to an aqueous pigment dispersion comprising low molecular weight polytrimethylene ether glycol. This disclosure is further directed to an antimicrobial aqueous pigment dispersion comprising the low molecular weight polytrimethylene ether glycol. The pigment dispersion can be used in coating compositions as interior and exterior top coats, basecoats, primers, primer surfacers and primer fillers. The disclosure is particularly directed to an aqueous pigment dispersion comprising components derived from renewable resources.

ANTIMICROBIAL COMPOSITIONS COMPRISING TRIMETHYLENE GLYCOL OLIGOMER AND METHODS OF USING THE COMPOSITIONS

Disclosed are antimicrobial compositions, and methods for killing, inhibiting, or preventing the growth of microbes, using trimethylene glycol oligomers or dimers. The trimethylene glycol oligomers and dimers have the formula R(CH2CH2CH2—O—CH2CH2CH2)nR1 where R and R1 are hydroxyl, amine, or ester functionalitiess, and n is 2 or higher. The antimicrobial compositions are useful in personal care and cosmetic compositions

AZOLE DERIVATIVES AS WTN PATHWAY INHIBITORS

The present invention relates to new compounds of formula I, to processes for their preparation, to pharmaceutical formulations containing such compounds and to their use in therapy. Such compounds find particular use in the treatment and/or prevention of conditions or diseases which are affected by over-activation of signaling in the Wnt pathway. For example, these may be used in preventing and/or retarding proliferation of tumor cells, for example carcinomas such as colon carcinomas.

ETHER COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES

The present invention relates to novel ether compounds, compositions comprising ether compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising an ether compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

Method for removal of MW176 cyclic acetal formed during the production of 1,3-propanediol

The present invention is an improvement upon the process for the production of 1,3-propanediol (PDO) wherein an aqueous solution of 3-hydroxypropanal (HPA) is formed, and the HPA is subjected to hydrogenation to produce a crude PDO mixture comprising PDO, water, MW176 acetal, and high and low volatility materials, wherein the crude PDO mixture is dried to produce a first overhead stream comprising water and some high volatility materials and a dried crude PDO mixture as a first distillate bottoms stream comprising PDO, MW176 acetal, and low volatility materials, and wherein the dried crude PDO mixture is distilled to produce a second overhead stream comprising some high volatility materials, a middle stream comprising PDO and MW176 acetal, and a second distillate bottoms stream comprising PDO and low volatility materials. The improvement on this process comprises treating the crude PDO mixture and/or the dried crude PDO mixture and/or the PDO product with an acidic zeolite, an acid form cation exchange resin, or a soluble acid to convert the MW176 cyclic acetal to more volatile materials which can be easily separated from PDO by distillation.

Solid acid catalyzed reactive stripping of impurities formed during the production of 1, 3-propanediol

A process for producing 1,3-propanediol comprising the steps of: a) forming an aqueous solution of 3-hydroxypropanal, b) hydrogenating the 3-hydroxypropanal to form a first crude 1,3-propanediol mixture comprising 1,3-propanediol, water, and MW 132 cyclic acetal, c) distilling the first crude 1,3-propanediol mixture to remove water and low boiling impurities and form a second crude 1,3-propanediol mixture, d) contacting the second crude 1,3-propanediol mixture with a solid acid purifier at a temperature of from about 50 to about 250° C. to convert the MW 132 cyclic acetal to more volatile cyclic acetals, and e) separating the more volatile cyclic acetals from the 1,3-propanediol by distillation or gas stripping.

Preparation of Discrete Oligoethers: Synthesis of Pentabutylene Glycol and Hexapropylene Glycol by Two Complementary Methods

Two experimentally facile methods for the preparation of discrete oligoethers are reported. The first involves an iterative sequence of oxidation, acetal formation, and reductive ring opening for the synthesis of penta-1,4-butylene glycol. The second method is also iterative, comprising phase-transfer etherification and end-group deprotection to form hexa-1,3-propylene glycol. These methods offer significantly improved yields and purification protocols over previously reported syntheses.

Solid state stereochemistry of crown ethers: X-ray crystal structure and 13C NMR studies of the LiNCS complex of 1,4,7,11-tetraoxacyclotetradecane

The title complex is asymmetric in the crystal due to the spatial orientation of the NCS function. The space group has been determined to be P21 with a = 9.496(3), b = 8.736(3), c = 9.676(3) A, β = 117.859(5)°, and Z = 2. The solid state 13C NMR spectrum is consistent with the lack of symmetry in the crystal and there is little evidence for large amplitude motion in the macrocycle as determined from the dipolar dephased spectrum.